Multiple endocrine neoplasia type 1 (MEN1)
Rare autosomal dominant tumor predisposition syndrome (germline MEN1 mutation 11q13 encoding menin) with >95% lifetime penetrance by age 50. The 'three Ps' define the clinical syndrome: parathyroid (~95% primary hyperparathyroidism — usually first manifestation in 20s-30s), pituitary (~30-40% anterior pituitary adenomas — prolactinoma most common; also GH-secreting causing acromegaly, ACTH-secreting causing Cushing's disease, and non-functioning), and pancreatic/duodenal NETs (gastrinomas driving Zollinger-Ellison; insulinomas; glucagonomas; VIPomas; non-functioning pNETs — ~50% lifetime pancreatic NET risk). Additional manifestations: foregut carcinoids (thymic NETs especially aggressive in male smokers, bronchial, gastric), adrenocortical tumors (~40% usually non-functioning), facial angiofibromas + collagenomas + lipomas (cutaneous), meningiomas + ependymomas (CNS). Diagnostic criteria: ≥2 of 3 main tumor types, or 1 main tumor in first-degree relative of MEN1 patient, or pathogenic germline MEN1 variant. Cascade genetic testing of first-degree relatives is part of the care model. Surveillance per Thakker 2012 Clinical Practice Guidelines + Endocrine Society + ESE: annual calcium + PTH from age 8; gastrin from age 20; glucose/insulin/proinsulin from age 5; prolactin + IGF-1 from age 5; pancreatic imaging (MRI + EUS) every 1-3 years from age 10; pituitary MRI every 3-5 years from age 5; thymic/bronchial imaging every 1-2 years from age 15-20. Management: subtotal vs total parathyroidectomy for primary HPT (recurrence high — subtotal preferred; cinacalcet adjunct); high-dose PPIs (omeprazole, lansoprazole) for ZES gastrinomas; surgical resection for insulinomas + selected NETs; SSAs (octreotide, lanreotide) for symptomatic functioning NETs; DA therapy for prolactinoma; standard pituitary management for GH-secreting or ACTH-secreting adenomas. 177Lu-DOTATATE Lutathera PRRT (NETTER-1 + NETTER-2) for somatostatin-receptor-positive metastatic NETs from pancreatic/duodenal primaries = one TRUE peptide therapy with MEN1-relevant indication. AMEN (Association for Multiple Endocrine Neoplasia Disorders) is patient advocacy. **Editorial**: GH-axis peptides (CJC-1295, tesamorelin, ipamorelin) functionally contraindicated by 30-40% pituitary adenoma risk + tesamorelin FDA label contraindicates pituitary tumor history; SEMAGLUTIDE coordinated-care decision given ~50% lifetime pancreatic NET risk + chart-clarity issue (GLP-1 boxed warning names MEN2 specifically, not MEN1 — must be explicit in chart); BPC-157 angiogenesis profile uncharacterized in multi-organ tumor surveillance population; NMN does not engage menin biology. Fifty-fifth deliberate non-elevation.
What changes during this transition
MEN1 is a rare autosomal dominant tumor predisposition syndrome (germline MEN1 mutation on 11q13 encoding menin) with >95% lifetime penetrance by age 50, characterized by the 'three Ps' — parathyroid (~95% develop primary hyperparathyroidism, usually the first manifestation in the 20s-30s), pituitary (~30-40% develop anterior pituitary adenomas — prolactinoma most common, also GH-secreting acromegaly, ACTH-secreting Cushing's, and non-functioning), and pancreatic/duodenal neuroendocrine tumors (gastrinomas driving Zollinger-Ellison syndrome, insulinomas, glucagonomas, VIPomas, and non-functioning pNETs). MEN1 also predisposes to foregut carcinoids (thymic NETs especially aggressive in male smokers, bronchial, gastric), adrenocortical tumors (~40% but usually non-functioning), facial angiofibromas + collagenomas + lipomas, and CNS tumors (meningiomas, ependymomas). Patients live with this diagnosis from childhood onward — biochemical surveillance per Thakker 2012 Clinical Practice Guidelines and the Endocrine Society / European Society of Endocrinology starts as early as age 5 (prolactin, IGF-1, glucose/insulin/proinsulin), with annual calcium + PTH from age 8, gastrin from age 20, and serial pancreatic MRI + EUS every 1-3 years from age 10, pituitary MRI every 3-5 years from age 5, and thymic/bronchial imaging every 1-2 years from age 15-20. Cascade genetic testing of first-degree relatives is part of the care model, and the psychological weight of lifelong multi-organ tumor surveillance and family screening obligations is significant. Editorial substrate framing: MEN1 belongs in /ask because patients reasonably probe peptides in the context of their syndrome, and the honest answer in almost every case is that the peptide they are asking about (a) has no MEN1-specific characterization, (b) intersects the surveillance burden in ways the peptide clinic is not equipped to manage, and (c) belongs to a conversation with the endocrinologist running the surveillance program. The GH-axis peptides (CJC-1295, tesamorelin, ipamorelin) are functionally contraindicated in a syndrome where 30-40% of patients develop pituitary adenomas, and tesamorelin's label explicitly contraindicates pituitary tumor history. The GLP-1 class (semaglutide) requires coordinated care because MEN1 carries roughly 50% lifetime pancreatic NET risk and the boxed warning for MEN2 + medullary thyroid carcinoma creates prescribing-conversation confusion that needs explicit chart clarification. BPC-157's pro-angiogenic signaling sits awkwardly in a population on lifelong multi-organ tumor surveillance with no human characterization. NMN doesn't engage menin biology and shouldn't be positioned as disease-modifying in a syndrome with >95% lifetime penetrance. The one TRUE peptide therapy with an MEN1-relevant indication is 177Lu-DOTATATE (Lutathera) — peptide receptor radionuclide therapy targeting somatostatin-receptor-positive metastatic gastroenteropancreatic NETs, supported by NETTER-1 and NETTER-2 evidence — which is delivered by oncology-NET specialists, not peptide clinics, and which Juno covers as standard-of-care framing rather than community-peptide framing. Patient advocacy and education resources include the Association for Multiple Endocrine Neoplasia Disorders (AMEN) and the international guidelines bodies (Thakker / Endocrine Society / ESE / IGES). The deliberate non-elevation of peptide_slugs reflects the editorial posture: substrate exists for honest /ask answers when users probe; the discovery hub should not promote any community peptide as appropriate to surface against a multi-organ tumor predisposition syndrome with this surveillance burden.
Important caveat
MEN1 is multi-disciplinary endocrinology + endocrine surgery + endocrine oncology territory — care coordination across the team is the load-bearing intervention. **CHILDHOOD-ONSET SURVEILLANCE BURDEN**: biochemistry from age 5; pituitary MRI from age 5; calcium + PTH from age 8; pancreatic MRI + EUS from age 10; gastrin from age 20. **CASCADE FAMILY SCREENING** of first-degree relatives is part of the care model and obligation. **>95% LIFETIME PENETRANCE BY AGE 50** — this is high-penetrance autosomal dominant disease, not a risk modifier. **ZOLLINGER-ELLISON SYNDROME EMERGENCY**: gastrinomas drive severe peptic ulcer disease + bleeding + perforation risk if undiagnosed; high-dose PPI is the load-bearing intervention. **GH-AXIS PEPTIDES (CJC-1295, tesamorelin, ipamorelin, sermorelin, MK-677)**: functionally contraindicated by 30-40% MEN1 pituitary adenoma risk. Tesamorelin FDA label explicitly contraindicates pituitary tumor history. Treat the GH-axis class as one decision in MEN1 — they all stimulate the same axis. **SEMAGLUTIDE / GLP-1 AGONISTS**: coordinated-care decision, not absolute contraindication. Three load-bearing fronts: (1) ~50% lifetime pancreatic NET risk + active pancreatic surveillance interacts with GLP-1 pancreatic islet biology + pancreatitis-signal concerns; (2) MEN1 patients with GH-secreting adenomas develop acromegaly + secondary diabetes — manage the adenoma + GH excess upstream of the GLP-1 decision; (3) **CHART CLARITY ISSUE**: GLP-1 boxed warning names MEN2 specifically (with medullary thyroid carcinoma), NOT MEN1 — 'patient has MEN' written ambiguously creates downstream prescribing confusion. Insist on MEN1 (not MEN2) explicitly in the chart. **BPC-157**: no MEN1 characterization; pro-angiogenic VEGFR2-pathway signaling in animal models in a patient on multi-organ tumor surveillance is the wrong angle to handwave. **NMN**: general-aging NAD+ precursor; no engagement with menin biology; not disease-modifying in MEN1; doesn't displace surveillance adherence + family genetic counseling conversations. **177Lu-DOTATATE LUTATHERA** is the one TRUE peptide therapy with MEN1-NET indication — somatostatin-receptor-positive metastatic gastroenteropancreatic NETs per NETTER-1 + NETTER-2; delivered by NET-experienced oncology, not peptide clinics. AMEN (Association for Multiple Endocrine Neoplasia Disorders) is patient-side. Thakker 2012 + Endocrine Society + ESE + IGES are guideline references. WADA athletes: peptide GH secretagogues prohibited at all times. Pregnancy in MEN1 is high-risk; coordinate endocrinology + maternal-fetal medicine; preimplantation genetic testing options for cascade-affected family planning.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.